Table 6

MCII and participant responders based on changes between baseline and 8 weeks and between baseline and 6 months

Number with MCII (%)


Variables

Pearson's χ2

P values

OAK

Control


Preintervention to 8 weeks

WOMAC Physical Function, absolute

10.84(1, 141)

P = 0.001

25 (37%)

9 (13%)

WOMAC Physical Function (%)

19.34(1, 141)

P ≤ 0.001

29 (43%)

7 (10%)

SF-36 Physical Function

8.34(1, 140)

P = 0.006

40 (60%)

23 (34%)

SF-36 Pain

1.38(1, 139)

P = 0.265

23 (34%)

17 (25%)

VAS Pain, absolute

15.95(1, 139)

P ≤ 0.001

27 (40%)

7 (10%)

VAS Pain (%)

17.37(1, 139)

P ≤ 0.001

25 (37%)

5 (7%)

TUG

28.87(1, 139)

P ≤ 0.001

46 (69%)

15 (22%)

Responders

13.59(1, 141)

P ≤ 0.001

26 (39%)b

8 (12%)b

Preintervention to 6 months

WOMAC Physical Function, absolute

3.87(1, 135)

P = 0.057

24 (14%)

14 (20%)

WOMAC Physical Function (%)

4.37(1, 135)

P = 0.043

27 (40%)

15 (22%)

SF-36 Physical Function

2.93(1, 136)

P = 0.122

40 (60%)

29 (43%)

SF-36 Pain

0.95(1, 135)

P = 0.384

31 (46%)

25 (37%)

TUG

5.10(1, 132)

P = 0.036

38 (57%)

26 (38%)

Responders

2.58(1, 135)

P = 0.123

22 (33%)b

14 (20%)b


aMCII: minimal clinically important improvement; OARSI: Osteoarthritis Research International; OMERACT: Outcome Measures in Rheumatology; SF-36: Short Form 36 version 1 questionnaire; TUG: Timed Up & Go Test; VAS: Visual Analogue Scale; WOMAC: Western Ontario and McMaster Universities Arthritis Index. bData are number of responders based on the OMERACT-OARSI criteria [46].

Coleman et al. Arthritis Research & Therapy 2012 14:R21   doi:10.1186/ar3703

Open Data